Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
Eager RM, Cunningham CC, Senzer NN, Stephenson J Jr, Anthony SP, O'Day SJ, Frenette G, Pavlick AC, Jones B, Uprichard M, Nemunaitis J. Eager RM, et al. Among authors: nemunaitis j. BMC Cancer. 2009 Jul 30;9:263. doi: 10.1186/1471-2407-9-263. BMC Cancer. 2009. PMID: 19643020 Free PMC article. Clinical Trial.
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Laskin JJ, et al. Among authors: nemunaitis j. J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c. J Thorac Oncol. 2012. PMID: 22198426 Free article. Clinical Trial.
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A. Nemunaitis J, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):35-41. doi: 10.1007/s00280-012-1963-2. Epub 2012 Oct 4. Cancer Chemother Pharmacol. 2013. PMID: 23053254 Free PMC article. Clinical Trial.
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ. Stephenson JJ, et al. Among authors: nemunaitis j. Lung Cancer. 2014 Feb;83(2):219-23. doi: 10.1016/j.lungcan.2013.11.020. Epub 2013 Dec 2. Lung Cancer. 2014. PMID: 24388167 Clinical Trial.
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A. Nemunaitis J, et al. Clin Cancer Res. 1998 May;4(5):1101-9. Clin Cancer Res. 1998. PMID: 9607566 Clinical Trial.
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Swisher SG, et al. Among authors: nemunaitis j. J Natl Cancer Inst. 1999 May 5;91(9):763-71. doi: 10.1093/jnci/91.9.763. J Natl Cancer Inst. 1999. PMID: 10328106 Clinical Trial.
396 results